To evaluate efficacy and tolerability of tyrosine kinase inhibitors in patients with iodine-refractory differentiated thyroid cancer (DTC).
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2018
At a glance
- Drugs Axitinib (Primary) ; Lenvatinib (Primary) ; Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 25 Nov 2018 New trial record